METASTATIC COLORECTAL CANCER

This study tests a combination of up to 4 experimental drugs (retifanlimab, TriAdeno vaccine, N-803, and SX-682) in people with metastatic colorectal cancer that has spread and not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors.…

This study tests a new drug called JS212, given together with other cancer medicines, in people whose colorectal cancer has spread and has not been treated before. The goal is to see if the combination is safe and can shrink tumors. About 80 adults will take part.

This study tests new drug combinations in people with metastatic colorectal cancer that has spread. The goal is to see if these treatments can shrink tumors or slow cancer growth. About 120 adults with measurable disease and good performance status will participate. The trial foc…

This study tests a new drug (BNT314) designed to help the immune system attack cancer, combined with another immune-boosting drug (BNT327) and chemotherapy. It is for people with advanced colorectal cancer that did not respond well to initial treatment or, in one part, for those …

This study is for people with advanced colorectal cancer that has a certain genetic makeup (RAS/BRAF wild type) in the tumor but shows a different genetic change (RAS mutation) in a blood test. The goal is to see if a combination of chemotherapy (FOLFIRI) plus a drug called bevac…

This early-phase study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, colorectal, or lung cancer) that have not responded to standard treatments. The drug works by blocking a key cancer growth signal (PI3Kα:RAS). The main goals are to find a safe …

This study tests a new investigational drug called telisotuzumab adizutecan combined with standard chemotherapy and targeted therapies for people with metastatic colorectal cancer (cancer that has spread). About 390 adults will receive either the new drug at different doses or st…

This study looks at how well a biosimilar version of bevacizumab (called Elovie) works and how safe it is for people with advanced colorectal cancer that has spread and cannot be removed by surgery. About 133 adults will be followed as they receive this drug as their first treatm…

This study tests a new combination of drugs for people with advanced colorectal cancer that has stopped responding to initial treatment. About 30 adults aged 18-75 will receive a mix of chemotherapy and targeted therapy. The goal is to see if this approach can slow or stop cancer…

This study tests a new combination of chemotherapy drugs (FLIRT) plus bevacizumab for people with a specific genetic type of metastatic colorectal cancer that has not been treated yet. The goal is to see if the treatment is safe and effective at delaying cancer growth. About 27 p…

This study tests a new drug called ulixertinib combined with cetuximab and/or encorafenib in people with advanced colorectal cancer that has spread or cannot be removed. The goal is to find the best dose that is safe. About 27 adults who have already tried EGFR or BRAF-targeted t…

This study compares a new drug, RPH-030, to an existing one, Vectibix, for people with a certain type of advanced colorectal cancer. About 180 participants will receive either drug along with standard chemotherapy. The goal is to see if the new drug works similarly and is as safe…

This study tests a new drug called EMB-01 in 54 adults with advanced colorectal cancer that has come back or spread. Participants are randomly assigned to receive the drug once weekly or once weekly for 6 weeks then every two weeks. The goal is to see which schedule works better …

This early-stage trial tests a new treatment made from a patient's own tumor-fighting immune cells (TILs) for metastatic colorectal or prostate cancer. The main goals are to see if it is safe and if repeated doses are possible. About 12 adults will receive the therapy and be moni…

This study tests several targeted therapies (drugs that attack specific cancer cell features) in people with metastatic colorectal cancer that has spread. Participants receive treatment based on their tumor's unique biomarkers. The goal is to see if these personalized approaches …

This study tests a new drug called precemtabart tocentecan, alone or with bevacizumab, against a standard treatment for metastatic colorectal cancer that has not responded to prior therapies. About 1,020 adults who have already tried up to two prior treatments will participate. T…

This study tests whether adding two drugs (cetuximab and envafolimab) to a strong chemotherapy regimen helps people with a specific type of advanced colorectal cancer live longer without the disease getting worse. About 198 adults with left-sided, RAS/BRAF wild-type, MSS colorect…

This study tests a new treatment for people with advanced cancers of the digestive tract, breast, ovary, or other organs. Doctors take immune cells from a patient's tumor, grow them in a lab, and give them back along with a drug called pembrolizumab. The goal is to see if this co…

This study tests an experimental drug called ART0380 in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find a safe dose and see if it works alone or with other chemotherapy drugs like gemcitabine or irinotecan. About 442 participants wi…

This study tests whether adding two targeted drugs (sotorasib and panitumumab) to standard chemotherapy helps people with a specific genetic form of metastatic colorectal cancer live longer without their cancer growing. About 450 people who have not had prior treatment for their …

This study tests whether a combination of three drugs (liposomal irinotecan, TAS102, and bevacizumab) can help people with metastatic colorectal cancer that has not responded to standard treatments. About 50 adults with mismatch repair proficient tumors who have already tried sev…

This study is for people with advanced colorectal cancer that has a specific genetic change called KRAS G12C and has not responded to at least one prior treatment. The trial tests a combination of three drugs (adagrasib, cetuximab, and cemiplimab) to see if they can help control …

This study tests a different chemotherapy drug (trifluridine/tipiracil) for people with metastatic colorectal or gastroesophageal cancer who have a genetic condition (DPD deficiency) that makes standard chemo very toxic. About 73 participants will receive this drug along with oth…

This study tests a drug called enfortumab vedotin in people with advanced colorectal or liver cancer that has spread or cannot be removed. Participants must have already tried at least one standard treatment. The goal is to see if the drug can shrink tumors or slow the disease. A…

This study tests whether ivonescimab, a drug that targets both PD-1 and VEGF, can help control metastatic colorectal cancer that has already been treated. About 90 adults with advanced colon or rectal cancer will receive the drug. The main goal is to check safety and side effects…

This study tests an experimental drug called RBS2418 in 150 adults with advanced colorectal cancer that has spread and is no longer responding to standard treatments. The drug works by helping the immune system recognize and attack cancer cells. Participants will receive either R…

This early-stage study tests a new treatment called CEA-PRIT 2.0 for people with metastatic colorectal cancer that has stopped responding to standard therapies. The treatment uses a two-step process to deliver a radioactive particle directly to cancer cells, aiming to control the…

This study tests whether combining two drugs, fruquintinib and tislelizumab, can help people with a specific type of advanced colorectal cancer that has not spread to the liver. The trial includes 140 adults whose cancer is stable (MSS/pMMR) and cannot be removed by surgery. The …

This study is gathering medical information and biological samples from 400 adults with a specific genetic mutation (BRAFV600E) in advanced colorectal cancer. The goal is to learn how this cancer is treated in real-world settings and how long patients live. No new treatments are …

This study aims to create a mindfulness program for people with metastatic colorectal cancer and their partners to help reduce stress. Researchers will interview about 48 patients, partners, and doctors to learn what topics and formats work best. The goal is to design a program t…

This study watches 1,000 people with metastatic colorectal cancer whose first chemotherapy stopped working. It aims to see which second or later treatments doctors choose and how well they work. No new drugs are tested; the goal is to learn from real-world practice.